Sanalda.comBETA

Economy

Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

Publication and source

PublicationSanalda Haber

SourceMarketWatch

Published

CategoryEconomy

Summary from the source publisher’s news feed.

Read the full story at source ↗